GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: ILV-094
Compound class:
Antibody
Comment: Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab [1]. |
| No information available. |
Summary of Clinical Use  |
| Fezakinumab (ILV-094) has reached Phase 2 for atopic dermatitis (NCT01941537 ongoing), rheumatoid arthritis (NCT00883896 completed) and Phase 1 for psoriasis (NCT00563524 completed). |
| Mechanism Of Action and Pharmacodynamic Effects |
| IL-22, an IL-10 superfamily cytokine, plays a key role during inflammatory responses. Blocking or neutralising anti-IL-22 antibodies inhibit IL-22 activity, thereby reducing inflammation. Fezakinumab binds IL-22, effectively preventing formation of the IL-22/IL-22 receptor complex and inhibiting downstream signalling. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00563524 | Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis | Phase 1 Interventional | Wyeth is now a wholly owned subsidiary of Pfizer | ||
| NCT00883896 | Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis | Phase 2 Interventional | Pfizer | ||
| NCT01941537 | Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis | Phase 2 Interventional | Rockefeller University | ||
